AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.Nicholas G. Cost, James I. Geller, Lindsay A. Renfro et al.|Journal of Clinical Oncology|2025Cited by 7
Impact of Medicaid Expansion on Stage at Diagnosis for US Adults with Pancreatic Cancer: a Population-Based StudyErin M. Mobley, Alexander S. Parker, Kim Vigal et al.|Journal of Racial and Ethnic Health Disparities|2023Cited by 5